AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 91_CD 17_CD Loans_NNPS Repayment_NNP 2004_CD 2003_CD dates_NNS $_$ m_CD $_$ m_CD Unsecured_JJ loans_NNS US_NNP dollars_NNS 7_CD %_NN Guaranteed_VBN debentures_NNS 2023 283 295_CD 5.4_CD %_NN Callable_JJ bond_NN 2014_CD 747_CD Others_NNS 2013_CD 8_CD Total_JJ unsecured_JJ 1,030_CD 303_CD Less_RBR :_: current_JJ instalments_NNS of_IN loans_NNS Loans_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN 1,030_CD 303_CD In_IN the_DT above_JJ table_NN ,_, loans_NNS are_VBP shown_VBN after_IN taking_VBG account_NN of_IN associated_VBN cross-currency_NN swaps_NNS see_VBP Note_NN 18_CD ._.
During_IN the_DT year_NN ,_, a_DT 5.4_CD %_NN callable_JJ bond_NN was_VBD issued_VBN for_IN proceeds_NNS ,_, net_NN of_IN expense_NN ,_, of_IN $_$ 747m_CD ._.
There_EX are_VBP no_DT loans_NNS from_IN banks_NNS included_VBD in_IN the_DT table_NN above_IN 2003_CD $_$ nil_JJ ._.
18_CD Financial_NNP instruments_NNS The_DT Groups_NNS objectives_NNS ,_, policies_NNS and_CC strategy_NN in_IN respect_NN of_IN risk_NN management_NN and_CC the_DT use_NN of_IN financial_JJ instruments_NNS are_VBP described_VBN in_IN the_DT Financial_NNP Review_NNP ._.
The_DT following_JJ disclosures_NNS exclude_VBP all_DT short_JJ term_NN ,_, trade_NN related_VBN debtors_NNS and_CC creditors_NNS ._.
Interest_NN rate_NN risks_NNS of_IN financial_JJ assets_NNS and_CC liabilities_NNS The_DT interest_NN rate_NN profile_NN ,_, after_IN taking_VBG into_IN account_NN interest_NN and_CC cross-currency_NN swaps_NNS ,_, of_IN the_DT financial_JJ assets_NNS and_CC liabilities_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2004_CD was_VBD :_: Financial_NNP Weighted_NNP Weighted_NNP assets_NNS liabilities_NNS average_JJ average_NN on_IN which_WDT fixed_JJ period_NN for_IN Floating_VBG Fixed_VBN no_DT interest_NN is_VBZ interest_NN which_WDT rate_NN rate_NN rate_NN paid_VBD received_VBN Total_JJ rate_NN is_VBZ fixed_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD %_NN Years_NNS Financial_NNP liabilities_NNS US_NNP dollar_NN 1,159_CD 1,159_CD Other_JJ 13_CD 13_CD 1,172_CD 1,172_CD Financial_NNP assets_NNS US_NNP dollar_NN 4,772_CD 10_CD 4,782_CD Euro_NNP 4_CD 4_CD Sterling_NNP 127 252 379_CD SEK_NNP 2_CD 18_CD 20_CD Other_JJ 228_CD 228_CD 5,133_CD 280_CD 5,413_CD The_DT floating_VBG rate_NN financial_JJ liabilities_NNS comprise_VBP largely_RB of_IN fixed_JJ rate_NN debt_NN that_WDT has_VBZ been_VBN swapped_VBN into_IN floating_VBG rate_NN debt_NN ._.
During_IN the_DT year_NN ,_, the_DT Group_NNP restructured_VBD its_PRP$ external_JJ debt_NN ._.
A_DT $_$ 300m_CD US_NNP dollar_NN bond_NN was_VBD partially_RB re-purchased_JJ and_CC canceled_VBN ,_, with_IN the_DT remaining_VBG balance_NN swapped_VBD into_IN floating_VBG rate_NN until_IN maturity_NN ._.
In_IN addition_NN ,_, the_DT Group_NNP issued_VBD a_DT $_$ 750m_CD US_NNP dollar_NN fixed_VBN rate_NN bond_NN under_IN a_DT $_$ 4bn_CD SEC_NNP registered_VBD shelf_NN program_NN ._.
The_DT bond_NN matures_VBZ in_IN 2014_CD and_CC has_VBZ been_VBN swapped_VBN to_TO floating_VBG rate_NN until_IN maturity_NN ._.
The_DT financial_JJ liabilities_NNS also_RB include_VBP $_$ 142m_CD of_IN short_JJ term_NN bank_NN borrowings_NNS and_CC overdrafts_NNS ,_, bearing_VBG interest_NN at_IN rates_NNS fixed_VBN by_IN reference_NN to_TO local_JJ interbank_NN rates_NNS ._.
The_DT financial_JJ assets_NNS principally_RB comprise_VBP cash_NN on_IN overnight_JJ deposit_NN or_CC held_VBN directly_RB with_IN third_JJ party_NN fund_NN managers_NNS and_CC short_JJ term_NN investments_NNS with_IN an_DT average_JJ maturity_NN of_IN 27_CD days_NNS ._.
These_DT include_VBP deposits_NNS where_WRB the_DT interest_NN rate_NN is_VBZ fixed_VBN until_IN maturity_NN but_CC ,_, as_IN the_DT original_JJ maturity_NN is_VBZ less_JJR than_IN one_CD year_NN ,_, they_PRP are_VBP classified_VBN as_IN floating_VBG rate_NN financial_JJ instruments_NNS ._.
The_DT main_JJ benchmark_NN rates_NNS for_IN euro_NN and_CC US_NNP dollar_NN financial_JJ assets_NNS are_VBP the_DT relevant_JJ LIBID_NNP rates_NNS ._.
Financial_JJ assets_NNS include_VBP $_$ 267m_CD of_IN other_JJ fixed_JJ asset_NN investments_NNS on_IN which_WDT no_DT interest_NN is_VBZ received_VBN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 92_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 18_CD Financial_NNP instruments_NNS continued_VBD Currency_NNP exposures_NNS 100_CD %_NN of_IN the_DT Groups_NNS major_JJ transactional_JJ currency_NN exposures_NNS on_IN working_VBG capital_NN balances_NNS ,_, which_WDT typically_RB extend_VBP for_IN up_RB to_TO three_CD months_NNS ,_, are_VBP hedged_VBN using_VBG forward_RB foreign_JJ exchange_NN contracts_NNS ._.
As_IN a_DT result_NN ,_, as_RB at_IN 31_CD December_NNP 2004_CD and_CC 31_CD December_NNP 2003_CD ,_, there_EX were_VBD no_DT material_NN monetary_JJ assets_NNS or_CC liabilities_NNS in_IN currencies_NNS other_JJ than_IN the_DT functional_JJ currencies_NNS of_IN the_DT Group_NNP companies_NNS concerned_VBN ,_, having_VBG taken_VBN into_IN account_NN the_DT effect_NN of_IN forward_RB exchange_NN currency_NN contracts_NNS that_WDT have_VBP been_VBN used_VBN to_TO match_VB foreign_JJ currency_NN exposures_NNS ._.
Additionally_RB ,_, approximately_RB 95_CD %_NN of_IN forecast_NN future_JJ foreign_JJ currency_NN transaction_NN exposures_NNS on_IN major_JJ currencies_NNS extending_VBG for_IN 12_CD months_NNS were_VBD hedged_VBN to_TO cover_VB movements_NNS outside_IN specified_VBN limits_NNS ._.
The_DT principal_JJ currency_NN exposures_NNS sterling_NN ,_, Swedish_JJ kronor_NNS SEK_NNP and_CC euros_NNS were_VBD hedged_VBN using_VBG a_DT mixture_NN of_IN purchased_JJ currency_NN options_NNS and_CC forward_RB foreign_JJ exchange_NN contracts_NNS ._.
As_IN at_IN 31_CD December_NNP 2004_CD ,_, the_DT forecast_NN future_JJ foreign_JJ currency_NN transaction_NN exposures_NNS were_VBD :_: 2004_CD 2003_CD Forecast_NNP Forecast_NNP exposures_NNS exposures_NNS $_$ m_CD $_$ m_CD Sterling_NN payables_NNS 2,553_CD 2,517_CD SEK_NNP payables_NNS 1,551_CD 1,442_CD Euro_NNP receivables_NN 1,926_CD 2,194_CD Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS ,_, other_JJ than_IN short_JJ term_NN creditors_NNS such_JJ as_IN trade_NN creditors_NNS and_CC accruals_NNS ,_, at_IN 31_CD December_NNP 2004_CD was_VBD as_IN follows_VBZ :_: 2004_CD 2003_CD Analysis_NN by_IN year_NN of_IN repayment_NN Loans_NNP Other_JJ Total_NNP Loans_NNPS Other_JJ Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD After_IN five_CD years_NNS 1,030_CD 1,030_CD 303_CD 303_CD From_IN five_CD to_TO four_CD years_NNS From_IN four_CD to_TO three_CD years_NNS From_IN three_CD to_TO two_CD years_NNS From_IN two_CD to_TO one_CD years_NNS Due_JJ after_IN more_JJR than_IN one_CD year_NN 1,030_CD 1,030_CD 303_CD 303_CD Due_JJ within_IN one_CD year_NN 142 142 152 152_CD 1,030_CD 142_CD 1,172_CD 303 152 455_CD Other_JJ financial_JJ liabilities_NNS comprise_VBP short_JJ term_NN bank_NN borrowings_NNS and_CC overdrafts_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 93_CD 18_CD Financial_NNP instruments_NNS continued_VBD Borrowing_NNP facilities_NNS The_DT Group_NNP currently_RB relies_VBZ on_IN its_PRP$ cash_NN balances_NNS and_CC short_JJ term_NN investments_NNS excluding_VBG investment_NN securities_NNS of_IN $_$ 4,990_CD m_NN and_CC long_JJ term_NN debt_NN of_IN $_$ 1,030_CD m_NN to_TO manage_VB liquidity_NN risk_NN ._.
Fair_NNP values_NNS of_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS Set_VBP out_RP below_IN is_VBZ a_DT comparison_NN by_IN category_NN of_IN carrying_VBG values_NNS and_CC fair_JJ values_NNS of_IN all_PDT the_DT Groups_NNS financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS as_IN at_IN 31_CD December_NNP 2004_CD and_CC 31_CD December_NNP 2003_CD ._.
2004 2004 2003 2003_CD Carrying_VBG Fair_NNP Carrying_VBG Fair_NNP value_NN value_NN value_NN value_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Primary_JJ financial_JJ instruments_NNS Short_JJ term_NN borrowings_NNS and_CC overdrafts_NNS 142 142 152 152_CD Loans_NNPS 1,030_CD 1,126_CD 303_CD 371_CD Cash_NN 1,055_CD 1,055_CD 733_CD 733_CD Short_JJ term_NN investments_NNS 4,091_CD 4,095_CD 3,218_CD 3,306_CD Fixed_VBN asset_NN investments_NNS 267 262 220 217_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT interest_NN rate_NN and_CC currency_NN profile_NN Cross-currency_NN swaps_NNS and_CC interest_NN rate_NN swaps_NNS 71_CD 56_CD Derivative_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO hedge_VB the_DT currency_NN exposure_NN on_IN existing_VBG transactions_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS 910_CD 12_CD 12_CD Derivative_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO hedge_VB the_DT currency_NN exposure_NN on_IN expected_JJ future_JJ transactions_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS 19_CD Foreign_JJ currency_NN option_NN contracts_NNS 22_CD 32_CD 77_CD 148_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 94_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 18_CD Financial_NNP instruments_NNS continued_VBD The_DT methods_NNS and_CC assumptions_NNS used_VBN to_TO estimate_VB the_DT fair_JJ values_NNS of_IN financial_JJ instruments_NNS are_VBP as_IN follows_VBZ :_: a._VB Short_JJ term_NN investments_NNS the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS ._.
For_IN unlisted_JJ investments_NNS ,_, carrying_VBG values_NNS approximate_JJ fair_JJ value_NN ._.
Fixed_JJ asset_NN investments_NNS excluding_VBG equity_NN investments_NNS in_IN joint_JJ ventures_NNS and_CC associates_NNS the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS ._.
c._FW Loans_NNPS the_DT fair_JJ value_NN of_IN publicly_RB traded_VBN debt_NN is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS :_: the_DT fair_JJ value_NN of_IN floating_VBG rate_NN debt_NN is_VBZ nominal_JJ value_NN ,_, as_IN mark_NN to_TO market_NN differences_NNS would_MD be_VB minimal_JJ given_VBN frequency_NN of_IN resets_NNS :_: the_DT fair_JJ value_NN of_IN remaining_VBG debt_NN is_VBZ estimated_VBN using_VBG appropriate_JJ zero_CD coupon_NN valuation_NN techniques_NNS based_VBN on_IN rates_NNS current_JJ at_IN year_NN end_NN ._.
d._FW Forward_RB foreign_JJ exchange_NN contracts_NNS the_DT Group_NNP has_VBZ forward_RB foreign_JJ exchange_NN contracts_NNS to_TO sell_VB currency_NN for_IN the_DT purpose_NN of_IN hedging_VBG non-dollar_JJ commercial_JJ transaction_NN exposures_NNS which_WDT existed_VBD at_IN the_DT date_NN of_IN the_DT balance_NN sheet_NN and_CC to_TO hedge_VB anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, non-dollar_JJ commercial_JJ transactions_NNS for_IN 2005_CD ._.
The_DT majority_NN of_IN the_DT contracts_NNS for_IN existing_VBG transactions_NNS had_VBD a_DT maturity_NN of_IN six_CD months_NNS or_CC less_JJR from_IN year_NN end_NN ._.
The_DT fair_JJ value_NN of_IN forward_RB foreign_JJ exchange_NN contracts_NNS is_VBZ based_VBN on_IN market_NN forward_RB foreign_JJ exchange_NN rates_NNS at_IN year_NN end_NN ._.
e._FW Foreign_JJ currency_NN option_NN contracts_NNS the_DT Group_NNP has_VBZ foreign_JJ currency_NN option_NN contracts_NNS to_TO hedge_VB anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, non-dollar_JJ commercial_JJ transactions_NNS for_IN 2005_CD ._.
The_DT fair_JJ value_NN of_IN option_NN contracts_NNS is_VBZ estimated_VBN using_VBG Black-Scholes_NNP valuation_NN techniques_NNS ._.
f._FW Interest_NN rate_NN and_CC cross-currency_NN swaps_NNS AstraZeneca_NNP uses_VBZ interest_NN rate_NN and_CC cross-currency_NN swaps_NNS to_TO hedge_VB the_DT Groups_NNS exposure_NN to_TO fluctuations_NNS in_IN interest_NN rates_NNS and_CC foreign_JJ exchange_NN movements_NNS on_IN borrowings_NNS ,_, in_IN accordance_NN with_IN a_DT formal_JJ risk_NN management_NN strategy_NN ._.
The_DT fair_JJ value_NN is_VBZ estimated_VBN using_VBG appropriate_JJ zero_CD coupon_NN valuation_NN techniques_NNS based_VBN on_IN rates_NNS current_JJ at_IN year_NN end_NN ._.
The_DT above_JJ financial_JJ instruments_NNS are_VBP subject_JJ to_TO credit_NN and_CC market_NN risk_NN ._.
AstraZeneca_NNP contains_VBZ credit_NN risk_NN through_IN the_DT use_NN of_IN counterparty_NN and_CC product_NN specific_JJ credit_NN limits_NNS and_CC by_IN ongoing_JJ review_NN procedures_NNS ._.
All_DT financial_JJ instruments_NNS are_VBP transacted_VBN with_IN commercial_JJ banks_NNS and_CC ,_, in_IN line_NN with_IN standard_JJ market_NN practice_NN ,_, are_VBP not_RB backed_VBN with_IN cash_NN collateral_NN ._.
The_DT notional_JJ principal_NN values_NNS of_IN off_JJ balance_NN sheet_NN financial_JJ instruments_NNS do_VBP not_RB represent_VB amounts_NNS exchanged_VBN by_IN the_DT parties_NNS and_CC are_VBP not_RB a_DT measure_NN of_IN the_DT credit_NN risk_NN to_TO the_DT Group_NNP of_IN these_DT instruments_NNS ._.
The_DT credit_NN risk_NN of_IN these_DT instruments_NNS is_VBZ limited_VBN to_TO the_DT positive_JJ fair_JJ values_NNS of_IN such_JJ contracts_NNS ._.
Market_NN risk_NN is_VBZ the_DT sensitivity_NN of_IN the_DT value_NN of_IN financial_JJ instruments_NNS to_TO changes_NNS in_IN related_JJ currency_NN and_CC interest_NN rates_NNS ._.
The_DT Group_NNP is_VBZ not_RB exposed_VBN to_TO material_NN market_NN risk_NN because_IN gains_NNS and_CC losses_NNS on_IN the_DT derivative_JJ financial_JJ instruments_NNS are_VBP largely_RB offset_VBN by_IN gains_NNS and_CC losses_NNS on_IN the_DT underlying_VBG assets_NNS ,_, liabilities_NNS and_CC transactions_NNS subject_JJ to_TO hedge_VB ._.
Hedges_NNP As_IN noted_VBN on_IN page_NN 92_CD ,_, the_DT Groups_NNS policy_NN is_VBZ to_TO hedge_VB 100_CD %_NN of_IN transactional_JJ currency_NN exposures_NNS and_CC approximately_RB 95_CD %_NN of_IN forecast_NN future_JJ transaction_NN exposures_NNS using_VBG forward_RB foreign_JJ exchange_NN contracts_NNS and_CC foreign_JJ currency_NN option_NN contracts_NNS ._.
It_PRP also_RB uses_VBZ cross-currency_NN and_CC interest_NN rate_NN swaps_NNS to_TO manage_VB the_DT profile_NN of_IN its_PRP$ borrowings_NNS ._.
Gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP not_RB recognized_VBN until_IN the_DT exposure_NN that_WDT is_VBZ being_VBG hedged_VBN is_VBZ itself_PRP recognized_VBN ._.
Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP as_IN follows_VBZ :_: Total_JJ net_JJ Gains_NNS Losses_NNS gains_VBZ $_$ m_CD $_$ m_CD $_$ m_CD Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2004_CD 129_CD 21_CD 108_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD recognized_VBN in_IN 2004_CD 105_CD 21_CD 84_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD not_RB recognized_VBN in_IN 2004_CD 24_CD 24_CD Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2004_CD 83_CD 1_CD 82_CD Gains_NNS and_CC losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2005_CD 33_CD 1_CD 32_CD Gains_NNS and_CC losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2006_CD or_CC later_RB 50_CD 50_CD
